Browsing Tag

VV116

Junshi Biosciences Announces Acceptance of NDA for VV116 in China

Eli Pacheco Jan 18, 2023 0

SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical…

Health

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to…

Eli Pacheco May 25, 2022 0

--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint --VV116 has a favorable safety profile and fewer adverse events than PAXLOVID…

Health

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial…

Eli Pacheco Mar 16, 2022 0

SHANGHAI, China, March 16, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical…